RA
ATXS

Rosalind Advisors’s Astria Therapeutics ATXS Stock Holding History

Rosalind Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-152,853
Closed -$1.11M – 40
2025
Q3 		$1.11M Buy
+152,853
New +$1.03M 0.38% 29
2024
Q1 		– Sell
-1,128,708
Closed -$8.67M – 35
2023
Q4 		$8.67M Buy
+1,128,708
New +$6.24M 7.14% 3

Other funds holding ATXS

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Rosalind Advisors's ATXS Position: Q4 2025 in Review

Rosalind Advisors sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 152,853 shares — an estimated $1.11M sold.

Rosalind Advisors first reported a position in ATXS in Q4 2023 and held it in 2 quarters. The position peaked at $8.67M in Q4 2023. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Rosalind Advisors reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Rosalind Advisors sold 152,853 Astria Therapeutics shares in Q4 2025, an estimated $1.11M.
  • Rosalind Advisors first reported a position in Astria Therapeutics in Q4 2023 and held it in 2 quarters.
  • Rosalind Advisors's Astria Therapeutics position peaked at $8.67M in Q4 2023.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Rosalind Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.